Increased collection efficiency of CD34+ cells after mobilization with preemptive use of plerixafor followed by leukocytapheresis on the same day.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
08
10
2019
revised:
18
01
2020
accepted:
19
01
2020
pubmed:
18
2
2020
medline:
9
9
2020
entrez:
18
2
2020
Statut:
ppublish
Résumé
Plerixafor should be administered 6 to 11 hours before starting leukocytapheresis. However, we have been using plerixafor followed by leukocytapheresis according to different time schedules since 2007. Our objective was to compare the CD34+ cell collection efficiency (CE1) of the first leukocytapheresis performed after using plerixafor at different time intervals. Same-day schedule refers to the administration of plerixafor at 10:00 AM and starting the leukocytapheresis on the same day at 4:00 PM (6 hours interval). Next-day schedule refers to the administration of plerixafor at 8:00 PM and starting the leukocytapheresis on the next day (10:00 AM or 4:00 PM; either a 14- or 20-hr interval). Variables that might influence the CE1 of CD34+ cells were analyzed by longitudinal linear regression with a random effects model derived by generalized estimating equations. The median CE1 of CD34+ cells was higher in the group of 30 patients who underwent leukocytapheresis on the same day when compared with the group of 62 patients who underwent leukocytapheresis on the next day (65.8% vs. 56.7%; p < 0.01). In the longitudinal linear regression analysis, only the time from plerixafor administration to leukocytapheresis start was associated with a statistically significant decrease in the CE1 of CD34+ cells (CE1 change -0.034%; p < 0.01). Higher CE1 of CD34+ cells was observed when patients underwent leukocytapheresis on the same day after receiving plerixafor in comparison with administering plerixafor and underwent leukocytapheresis on the next day. Larger studies are necessary to confirm present results.
Sections du résumé
BACKGROUND
Plerixafor should be administered 6 to 11 hours before starting leukocytapheresis. However, we have been using plerixafor followed by leukocytapheresis according to different time schedules since 2007. Our objective was to compare the CD34+ cell collection efficiency (CE1) of the first leukocytapheresis performed after using plerixafor at different time intervals.
STUDY DESIGN AND METHODS
Same-day schedule refers to the administration of plerixafor at 10:00 AM and starting the leukocytapheresis on the same day at 4:00 PM (6 hours interval). Next-day schedule refers to the administration of plerixafor at 8:00 PM and starting the leukocytapheresis on the next day (10:00 AM or 4:00 PM; either a 14- or 20-hr interval). Variables that might influence the CE1 of CD34+ cells were analyzed by longitudinal linear regression with a random effects model derived by generalized estimating equations.
RESULTS
The median CE1 of CD34+ cells was higher in the group of 30 patients who underwent leukocytapheresis on the same day when compared with the group of 62 patients who underwent leukocytapheresis on the next day (65.8% vs. 56.7%; p < 0.01). In the longitudinal linear regression analysis, only the time from plerixafor administration to leukocytapheresis start was associated with a statistically significant decrease in the CE1 of CD34+ cells (CE1 change -0.034%; p < 0.01).
CONCLUSION
Higher CE1 of CD34+ cells was observed when patients underwent leukocytapheresis on the same day after receiving plerixafor in comparison with administering plerixafor and underwent leukocytapheresis on the next day. Larger studies are necessary to confirm present results.
Substances chimiques
Antigens, CD34
0
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
plerixafor
S915P5499N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
779-785Subventions
Organisme : Sanofi España
Pays : International
Informations de copyright
© 2020 AABB.
Références
Gratwohl A, Pasquini MC, Aljurf M, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol 2015;2:e91-100.
Hübel K. Mobilization and collection of HSC. In: Carreras E, Dufour C, Mohty M et al., editors. The EBMT handbook. Hematopoietic stem cell transplantation and cellular therapies. Cham, Switzerland: Springer Nature Switzerland AG; 2019. p. 117-22.
Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010;150:647-62.
Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014;20:295-308.
Douglas KW, Gilleece M, Hayden P, et al. UKconsensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher 2018;33:46-59.
DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkinʼs lymphoma. J Clin Oncol 2009;27:4767-73.
DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6.
EMA. Plerixafor [monograph on the Internet]. ema.europa.eu: European Union; 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil
Lefrère F, Mauge L, Réa D, et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. Transfusion 2013;53:564-9.
Jantunen E, Partanen A, Valtola J, et al. Pre-emptive plerixafor injection in lymphoma patients mobilized with chemotherapy plus pegfilgrastim followed by apheresis on the same day. J Clin Apher 2017;32:594-6.
Cooper DL, Pratt K, Baker J, et al. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clin Lymphoma Myeloma Leuk 2011;11:267-72.
Harvey RD, Kaufman JL, Johnson HR, et al. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biol Blood Marrow Transplant 2013;19:1393-5.
Cid J, Carbasse G, Alba C, et al. Leukocytapheresis in nonmobilized donors for cellular therapy protocols: evaluation of factors affecting collection efficiency of cells. J Clin Apher 2019;34:672-9.
Cid J, Carbasse G, Cid-Caballero M, et al. The Barcelona Hospital Clinic therapeutic apheresis database. J Clin Apher 2018;33:259-64.
Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26.
Gratama JW, Kraan J, Keeney M, et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003;5:55-65.
Strasser EF, Zimmermann R, Weisbach V, et al. Mononuclear cell variability and recruitment in non-cytokine-stimulated donors after serial 10-liter leukapheresis procedures. Transfusion 2005;45:445-52.
Neyrinck MM, Vrielink H. Calculations in apheresis. J Clin Apher 2015;30:38-42.
Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44:1667-73.
Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30.
Hubel K, Liles WC, Broxmeyer HE, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004;1:165-72.
Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-8.
Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012;52:906-14.
Bilgin YM, de Greef GE. Plerixafor for stem cell mobilization: the current status. Curr Opin Hematol 2016;23:67-71.
Sancho JM, Duarte R, Medina L, et al. Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients. Med Clin (Barc) 2016;147:223.e1-7.
Shi PA, Miller LK, Isola LM. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor. Transfusion 2014;54:1263-8.
Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher 2017;32:224-34.
Visram A, Bredeson C, Allan D, et al. Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. Blood Cancer J 2018;8:14.
Zeller W, Gutensohn K, Stockschlader M, et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkinʼs disease, non-Hodgkinʼs lymphoma, and cancer of the testis. Bone Marrow Transplant 1996;17:709-13.
de Greef GE, Braakman E, van der Holt B, et al. The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study. Transfusion 2019;59:316-24.
Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood 2017;129:2680-92.
Gattillo S, Marktel S, Rizzo L, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion 2015;55:1993-2000.
Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica 2017;102:600-9.